A recent investigation has unveiled a noteworthy correlation, suggesting that individuals undergoing breast cancer surgery who exhibit suboptimal levels of vitamin D may experience heightened post-operative discomfort and a greater reliance on opioid-based pain relief. This discovery, detailed in the journal Regional Anesthesia & Pain Medicine, opens avenues for potentially optimizing patient care and recovery protocols. The implications of this study point towards a possible benefit from vitamin D supplementation for breast cancer patients with diagnosed deficiencies prior to undergoing procedures such as a modified radical mastectomy, a significant surgical intervention involving the removal of an entire breast.
While vitamin D is widely recognized for its indispensable role in maintaining skeletal integrity and bone health, a growing body of scientific evidence is beginning to underscore its broader physiological influence, including its potential impact on nociception, the process by which the body senses and interprets pain. Researchers hypothesize that vitamin D’s effects on modulating inflammatory pathways and its interactions with the immune system could be instrumental in shaping an individual’s pain perception and response. It is also noteworthy that vitamin D deficiency is a frequently observed condition among individuals diagnosed with breast cancer, a prevalence that spurred the current research endeavor to explore its potential influence on post-surgical pain experiences.
To empirically investigate this hypothesis, a prospective observational study was meticulously conducted at Fayoum University Hospital in Egypt, spanning from September 2024 to April 2025. This research design involved tracking a cohort of 184 women scheduled for a unilateral modified radical mastectomy, allowing for the observation of outcomes as they unfolded naturally over time without researcher intervention in treatment regimens. The observational nature of the study, coupled with its prospective design, enabled researchers to gather data on the participants’ experiences and pain trajectories following surgery.
The study cohort was bifurcated into two distinct groups based on their serum vitamin D concentrations: one group classified as vitamin D deficient, with levels falling below 30 nmol/L, and the other group exhibiting sufficient vitamin D levels, measured at or above 30 nmol/L. These two patient cohorts were intentionally selected to be as comparable as possible, with the vitamin D deficient group averaging 44 years of age and the vitamin D sufficient group averaging 42 years. This age similarity helped to minimize potential confounding variables that could influence pain perception.
Crucially, all participants received the hospital’s established standard of care, encompassing both intraoperative anesthesia and post-operative pain management strategies. A critical element of the study’s design was the blinding of the medical and nursing staff involved in patient care to the participants’ vitamin D status. This measure was implemented to mitigate any potential for bias, ensuring that the pain management decisions and interventions were not influenced by foreknowledge of a patient’s vitamin D levels. During the surgical procedure, all patients were administered fentanyl, a potent opioid analgesic employed for the management of acute perioperative pain. Following surgery, a standardized regimen of intravenous paracetamol was administered every eight hours to all participants. Furthermore, a patient-controlled analgesia (PCA) system was utilized, allowing patients to self-administer tramadol, another opioid analgesic, by pressing a button, within pre-set limits. This PCA system provided a precise and objective measure of the additional opioid medication each patient required for pain relief.
Throughout the initial 24-hour period post-surgery, participants’ pain intensity was systematically assessed at regular intervals: immediately after the procedure, and then at six, twelve, eighteen, and twenty-four hours. In addition to pain scores, researchers diligently recorded the incidence of nausea and vomiting, levels of sedation, and the duration of each patient’s hospital stay. A discernible divergence in pain experiences became apparent within the first day of recovery.
The data revealed that patients diagnosed with vitamin D deficiency were approximately three times more prone to reporting moderate to severe post-operative pain at any juncture during the initial 24-hour recovery period when contrasted with their counterparts who maintained adequate vitamin D levels. It is important to note that none of the participants, across either group, experienced pain that was classified as severe (rated 7 or higher on a 0-10 visual analog scale). The observed differences were predominantly attributable to instances of moderate pain, falling within the 4-6 range on the pain scale.
The disparity in pain perception was further mirrored in the quantity of pain medication required by the two groups. During the surgical procedure itself, patients in the vitamin D deficient group received, on average, a slightly higher dose of fentanyl, with an approximate difference of 8.25 µg. While this intraoperative difference was characterized as modest, the post-operative opioid consumption exhibited a more substantial divergence. Patients with insufficient vitamin D levels utilized significantly more tramadol via their PCA devices, averaging an additional 112mg compared to those with sufficient vitamin D. This increased reliance on opioid analgesics post-surgery carries considerable clinical significance due to the inherent risks associated with these medications, including potential side effects such as nausea, vomiting, drowsiness, and cognitive impairment, as well as the long-term risks of dependence and addiction.
Post-operative nausea was reported with greater frequency among the vitamin D deficient patient group. While vomiting did occur, it was exclusively observed within the deficient group, although the observed difference was marginal and did not reach statistical significance, meaning that chance could not be confidently ruled out as the primary explanatory factor.
Despite the compelling observations, the researchers were careful to emphasize the inherent limitations of their study design. As an observational study conducted at a single academic medical center, it is fundamentally incapable of establishing a definitive cause-and-effect relationship between vitamin D deficiency and increased post-operative pain or opioid consumption. Further research employing interventional study designs would be necessary to confirm such a causal link. Moreover, the study did not include measurements of inflammatory biomarkers, thus precluding an investigation into the specific biological mechanisms that might underpin the observed association between vitamin D status and pain modulation. The research also did not capture data on several other factors known to influence post-operative pain, including pre-operative psychological states such as anxiety and depression, the stage of the cancer, the specific type of cancer treatment received, or pre-existing sleep disturbances.
Nevertheless, the research team concluded that "Vitamin D deficiency is associated with a higher occurrence of moderate to severe postoperative pain and increased opioid consumption in patients undergoing unilateral modified radical mastectomy." They further posited that "Preoperative vitamin D supplementation in breast cancer patients with vitamin D levels below 30 nmol/L may have a role in modulating postoperative pain." These findings, while preliminary and requiring further validation, suggest a potential avenue for enhancing the perioperative care of breast cancer patients by addressing vitamin D levels as a modifiable factor in pain management. Future clinical trials are warranted to rigorously evaluate the efficacy and safety of pre-operative vitamin D supplementation as an adjunct strategy for optimizing pain control and potentially reducing opioid requirements in this patient population.



